glp-1 agonist gastroparesis Drug-Induced and Product Liability GLP-1 receptor agonists and delayed

He managed to identify several new peptides and hormones, which he continued to investigate when he established a small laboratory at State University of New York Downstate Medical Center in Brooklyn

10.1038/s41598-021-97967-0 Summary Keywords heart failure, GLP-1, glucagon-like peptide-1, clinical trials, cardiovascular disease, cardiovascular outcome studies, diabetes, obesity Citation Kreiner FF, Hovingh GKK and von Scholten BJ (2022) The potential of glucagon-like peptide-1 receptor agonists in heart failure

Figure 12: Photograph Professor Vincent Marks (1930-2023), credit: Seaton)

Knowing what to expect based on the clinical trial literature helps distinguish between expected effects and anomalies that warrant investigation

The presence of severe nonproliferative DR or proliferative DR requires comanagement with retinology and further intervention, including intravitreal injection and/or laser photocoagulation consistent with the clinical standard of care

Le Glau L, Rouault C, Osinski C, Prifti E, Soula HA, Debdat J, et al